Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone609-275-0500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.47 billion
Profitability
Miscellaneous
Employees4,500
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable
Integra Lifesciences (NASDAQ:IART) Frequently Asked Questions
What is Integra Lifesciences' stock symbol?
Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART."
When did Integra Lifesciences' stock split? How did Integra Lifesciences' stock split work?
Integra Lifesciences shares split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were distributed to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split.
How were Integra Lifesciences' earnings last quarter?
Integra Lifesciences Holdings Corp (NASDAQ:IART) released its quarterly earnings data on Thursday, October, 24th. The life sciences company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.03. The life sciences company earned $379.10 million during the quarter, compared to the consensus estimate of $376.85 million. Integra Lifesciences had a return on equity of 16.83% and a net margin of 3.99%. The firm's revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter last year, the company earned $0.59 EPS. View Integra Lifesciences' Earnings History.
When is Integra Lifesciences' next earnings date?
What guidance has Integra Lifesciences issued on next quarter's earnings?
Integra Lifesciences updated its FY19 earnings guidance on Thursday, October, 24th. The company provided earnings per share (EPS) guidance of $2.70-2.75 for the period, compared to the Thomson Reuters consensus estimate of $2.73. The company issued revenue guidance of $1.517-1.522 billion, compared to the consensus revenue estimate of $1.52 billion.
What price target have analysts set for IART?
9 brokers have issued 1 year target prices for Integra Lifesciences' shares. Their forecasts range from $50.00 to $75.00. On average, they anticipate Integra Lifesciences' stock price to reach $61.89 in the next twelve months. This suggests a possible upside of 0.3% from the stock's current price. View Analyst Price Targets for Integra Lifesciences.
What is the consensus analysts' recommendation for Integra Lifesciences?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra Lifesciences in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Integra Lifesciences.
What are Wall Street analysts saying about Integra Lifesciences stock?
Here are some recent quotes from research analysts about Integra Lifesciences stock:
- 1. According to Zacks Investment Research, "Integra LifeSciences exited the second quarter of 2019 on a strong note with better-than-expected results. Organic revenue growth was encouraging and was above the company’s expectation. Within global neurosurgery business, sales in dural access and repair increased in low-single digits on an organic basis with growth in both graft and sealant product lines. Benefiting from product launches and an enhanced sales force performance, the company envisions faster organic growth during the second half of 2019. On the flip side, escalating costs and expenses have been a major headwind for Integra Lifesciences. A tough competitive landscape adds to the woes. Overall, Integra LifeSciences outperformed its industry in the past three months." (9/2/2019)
- 2. Cantor Fitzgerald analysts commented, "We maintain our Neutral rating and 12-month price target of $50 on IART. Although we view IART’s long-range plan as impressive, we believe execution over the next few quarters is critical to restoring investor confidence in the stock. We think it is appropriate to stay on the sidelines at this time, but we might become more positive on the stock if the company were to execute on its integration and salesforce restructuring goals. We think IART is fairly valued at current levels, appropriately balancing the long-term opportunities with the risk of near-term disruption from the Codman acquisition and the changes to the OTT sales channel structure." (2/21/2019)
Has Integra Lifesciences been receiving favorable news coverage?
Media headlines about IART stock have been trending somewhat positive this week, InfoTrie reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Integra Lifesciences earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news articles about the life sciences company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Integra Lifesciences.
Who are some of Integra Lifesciences' key competitors?
Some companies that are related to Integra Lifesciences include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Steris (STE) and Varian Medical Systems (VAR).
What other stocks do shareholders of Integra Lifesciences own?
Who are Integra Lifesciences' key executives?
Integra Lifesciences' management team includes the folowing people:
- Mr. Peter J. Arduini, Pres, CEO & Director (Age 54)
- Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 76)
- Mr. Glenn G. Coleman, Corp. VP of International & CFO (Age 51)
- Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 56)
- Mr. Robert T. Davis Jr., Corp. VP and Pres of Orthopedics & Tissue Technologies (Age 60)
Who are Integra Lifesciences' major shareholders?
Integra Lifesciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (2.14%), Vaughan Nelson Investment Management L.P. (1.00%), Point72 Asset Management L.P. (0.92%), Fisher Asset Management LLC (0.85%), Tributary Capital Management LLC (0.57%) and Eagle Asset Management Inc. (0.25%). Company insiders that own Integra Lifesciences stock include Barbara B Hill, Christian S Schade, Daniel L Reuvers, Glenn Coleman, Jeffrey Mosebrook, John Mooradian, Joseph Vinhais, Keith Bradley, Kenneth Burhop, Lisa Evoli, Peter J Arduini, Raymond G Murphy, Rhonda Germany Ballintyn, Richard E Caruso and Stuart Essig. View Institutional Ownership Trends for Integra Lifesciences.
Which institutional investors are selling Integra Lifesciences stock?
IART stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, First Trust Advisors LP, Barclays PLC, Fisher Asset Management LLC, SG Americas Securities LLC, Squarepoint Ops LLC, Tributary Capital Management LLC and Russell Investments Group Ltd.. Company insiders that have sold Integra Lifesciences company stock in the last year include Christian S Schade, Daniel L Reuvers, Glenn Coleman, John Mooradian, Kenneth Burhop, Lisa Evoli, Peter J Arduini, Raymond G Murphy and Richard E Caruso. View Insider Buying and Selling for Integra Lifesciences.
Which institutional investors are buying Integra Lifesciences stock?
IART stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Castleark Management LLC, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, CWM LLC, State of Tennessee Treasury Department, Endurant Capital Management LP and Meritage Portfolio Management. Company insiders that have bought Integra Lifesciences stock in the last two years include Barbara B Hill and Rhonda Germany Ballintyn. View Insider Buying and Selling for Integra Lifesciences.
How do I buy shares of Integra Lifesciences?
Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Integra Lifesciences' stock price today?
One share of IART stock can currently be purchased for approximately $61.68.
How big of a company is Integra Lifesciences?
Integra Lifesciences has a market capitalization of $5.30 billion and generates $1.47 billion in revenue each year. The life sciences company earns $60.80 million in net income (profit) each year or $2.42 on an earnings per share basis. Integra Lifesciences employs 4,500 workers across the globe.View Additional Information About Integra Lifesciences.
What is Integra Lifesciences' official website?
How can I contact Integra Lifesciences?
Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]
MarketBeat Community Rating for Integra Lifesciences (NASDAQ IART)
MarketBeat's community ratings are surveys of what our community members think about Integra Lifesciences and other stocks. Vote "Outperform" if you believe IART will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IART will underperform the S&P 500 over the long term. You may vote once every thirty days.
